EP4691560A2 — Vmat2 inhibitor compounds, compositions, and methods relating thereto
Assigned to Neurocrine Biosciences Inc · Expires 2026-02-11 · 0y expired
What this patent protects
Methods are provided herein for treating psychiatric disorders relating to 22q11.2 deletion syndrome and for selecting subjects for treatment with a VMAT2 inhibitor. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof.
USPTO Abstract
Methods are provided herein for treating psychiatric disorders relating to 22q11.2 deletion syndrome and for selecting subjects for treatment with a VMAT2 inhibitor. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.